Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.
In this webinar, hear consultant dermatologists Dr Laura Savage and Dr Amy Foulkes as well as NIHR Clinician Scientist Professor Laura Coates share their approach to early management of skin and joint manifestations in patients with PsO. They discuss key predictors and identification of progression to PsA and GRAPPA treatment recommendations. Efficacy and safety data and head-to-head superiority versus ustekinumab for Cosentyx are also presented. Lastly, our specialists consider how to assess treatment success.
Want to be notified of upcoming webinars?
Click the button below
BAD, British Association of Dermatologists; BADBIR, British Association of Dermatologists Biologics and Immunomodulators Register; CRP, c-reactive protein; DMARD, disease-modifying anti-rheumatic drug; GP, general practitioner; MRI, magnetic resonance imaging; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis.